ReviewAntibiotics (Basel, Switzerland)2022
Nanostructured Antibiotics and Their Emerging Medicinal Applications: An Overview of Nanoantibiotics.
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 74 citations in OpenAlex.
- Engineering Nano-Antibiotics for Accelerating Wound Healing in Drug-Resistant Bacterial Infections.Molecules (Basel, Switzerland) · 2026Article
- Green Synthesis of Silver Nanoparticles Using Hypecoum pendulum L. Extract: In Vivo Anti-Hyperglycemic and In Vitro Antimicrobial Effects.Molecular biotechnology · 2026Article
- Insights into structure, toxicity and antibacterial potential of tungsten oxide-carbon nanocomposites coupled with antibiotics.Scientific reports · 2025Article
- Unveiling the Antibacterial Efficacy and Mechanistic Insights of MnOInternational journal of molecular sciences · 2025Article
- Cold Plasma as a Revolutionary Antimicrobial Modality: A Multifaceted Weapon Against Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2025Review
- Nano-engineered Antibiotic Formulation That Targets Chronic MRSA Infection.Applied biochemistry and biotechnology · 2025Article
- Advancements in Antibacterial Therapy: Feature Papers.Microorganisms · 2025Review
- Tetracyclines in Rheumatoid Arthritis: Dual Anti-Inflammatory and Immunomodulatory Roles, Effectiveness, and Safety Insights.Antibiotics (Basel, Switzerland) · 2025Review
- Harnessing Nanoparticles to Overcome Antimicrobial Resistance: Promises and Challenges.Current pharmaceutical design · 2025Review
- Synergistic antimicrobial nanofiber membranes based on metal incorporated silica nanoparticles as advanced antimicrobial layers.RSC advances · 2024Article
- Salmon-IgM Functionalized-PLGA Nanosystem for Florfenicol Delivery as an Antimicrobial Strategy againstNanomaterials (Basel, Switzerland) · 2024Article
- Eradication of Klebsiella pneumoniae pulmonary infection by silver oxytetracycline nano-structure.AMB Express · 2024Article
- Recent Research Progress on Polyamidoamine-Engineered Hydrogels for Biomedical Applications.Biomolecules · 2024Review
- Antimicrobial Feature of Nanoparticles in the Antibiotic Resistance Era: From Mechanism to Application.Advanced biomedical research · 2024Review
- Zinc oxide nanoparticles mediate bacterial toxicity in Mueller-Hinton Broth via ZnFrontiers in microbiology · 2024Article
- Unveiling the nanoworld of antimicrobial resistance: integrating nature and nanotechnology.Frontiers in microbiology · 2024Review
- The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation.Scientific reports · 2023Article
- Towards further understanding the applications of endophytes: enriched source of bioactive compounds and bio factories for nanoparticles.Frontiers in plant science · 2023Review
- 4-Dimensional printing: exploring current and future capabilities in biomedical and healthcare systems-a Concise review.Frontiers in bioengineering and biotechnology · 2023Review
- A fresh pH-responsive imipenem-loaded nanocarrier againstFrontiers in bioengineering and biotechnology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial strains resistant to antimicrobial treatments, such as antibiotics, have emerged as serious clinical problems, necessitating the development of novel bactericidal materials. Nanostructures with particle sizes ranging from 1 to 100 nanometers have appeared recently as novel antibacterial agents, which are also known as "nanoantibiotics". Nanomaterials have been shown to exert greater antibacterial effects on Gram-positive and Gram-negative bacteria across several studies. Antibacterial nanofilms for medical implants and restorative matters to prevent bacterial harm and antibacterial vaccinations to control bacterial infections are examples of nanoparticle applications in the biomedical sectors. The development of unique nanostructures, such as nanocrystals and nanostructured materials, is an exciting step in alternative efforts to manage microorganisms because these materials provide disrupted antibacterial effects, including better biocompatibility, as opposed to minor molecular antimicrobial systems, which have short-term functions and are poisonous. Although the mechanism of action of nanoparticles (NPs) is unknown, scientific suggestions include the oxidative-reductive phenomenon, reactive ionic metals, and reactive oxygen species (ROS). Many synchronized gene transformations in the same bacterial cell are essential for antibacterial resistance to emerge; thus, bacterial cells find it difficult to build resistance to nanoparticles. Therefore, nanomaterials are considered as advanced solution tools for the fields of medical science and allied health science. The current review emphasizes the importance of nanoparticles and various nanosized materials as antimicrobial agents based on their size, nature, etc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.